Inhibition of interferon-γ-induced nitric oxide production by 10-hydroxy-trans-2-decenoic acid through inhibition of interferon regulatory factor-8 induction

Cellular Immunology

Volumn 273, Issue 1, 2012, Pages 73-78

  Takahashi, Keita ^a   Sugiyama, Tsuyoshi ^a   Tokoro, Shunji ^a   Neri, Paola ^a   Mori, Hiroshi ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Fatty acid; Nuclear factor B; Royal jelly; Tumor necrosis factor

Indexed keywords

10 HYDROXY TRANS 2 DECENOIC ACID; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; NITRIC OXIDE; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION;

ANIMALS; CELL LINE; ENZYME ACTIVATION; FATTY ACIDS; FATTY ACIDS, MONOUNSATURATED; INTERFERON REGULATORY FACTORS; INTERFERON-GAMMA; MACROPHAGES; MICE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAT1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

APIS MELLIFERA; APOIDEA;

EID: 84856011716     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.11.004     Document Type: Article

References (46)

1. MacMicking J., Xie Q.W., Nathan C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 1997, 15:323-350.
2. Kroncke K.D., Fehsel K., Kolb-Bachofen V. Inducible nitric oxide synthase in human diseases. Clin. Exp. Immunol. 1998, 113:147-156.
3. Nagy G., Koncz A., Telarico T., Fernandez D., Ersek B., Buzas E., Perl A. Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res. Ther. 2010, 12:210.
4. Singh V.K., Mehrotra S., Narayan P., Pandey C.M., Agarwal S.S. Modulation of autoimmune diseases by nitric oxide. Immunol Res. 2000, 22:1-19.
5. Pavlick K.P., Laroux F.S., Fuseler J., Wolf R.E., Gray L., Hoffman J., Grisham M.B. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic. Biol. Med. 2002, 33:311-322.
6. Hogaboam C.M., Jacobson K., Collins S.M., Blennerhassett M.G. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 1995, 268:G673-G684.
7. Hokari R., Kato S., Matsuzaki K., Kuroki M., Iwai A., Kawaguchi A., Nagao S., Miyahara T., Itoh K., Sekizuka E., Nagata H., Ishii H., Miura S. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to chronic colitis. Free Radic. Biol. Med. 2001, 31:153-163.
8. Kankuri E., Vaali K., Knowles R.G., Lahde M., Korpela R., Vapaatalo H., Moilanen E. Suppression of acute experimental colitis by a highly selective inducible nitric-oxide synthase inhibitor, N-[3-(aminomethyl)benzyl]acetamidine. J. Pharmacol. Exp. Ther. 2001, 298:1128-1132.
9. Miller M.J., Sadowska-Krowicka H., Chotinaruemol S., Kakkis J.L., Clark D.A. Amelioration of chronic ileitis by nitric oxide synthase inhibition. J. Pharmacol. Exp. Ther. 1993, 264:11-16.
10. Rachmilewitz D., Karmeli F., Okon E., Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 1995, 37:247-255.
11. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 2004, 75:163-189.
12. Nelson N., Kanno Y., Hong C., Contursi C., Fujita T., Fowlkes B.J., O'Connell E., Hu-Li J., Paul W.E., Jankovic D., Sher A.F., Coligan J.E., Thornton A., Appella E., Yang Y., Ozato K. Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation. J. Immunol. 1996, 156:3711-3720.
13. Pine R., Canova A., Schindler C. Tyrosine phosphorylated p91 binds to a single element in the ISGF2/IRF-1 promoter to mediate induction by IFN alpha and IFN gamma, and is likely to autoregulate the p91 gene. EMBO J. 1994, 13:158-167.
14. Xie Q.W., Whisnant R., Nathan C. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J. Exp. Med. 1993, 177:1779-1784.
15. Martin E., Nathan C., Xie Q.W. Role of interferon regulatory factor 1 in induction of nitric oxide synthase. J. Exp. Med. 1994, 180:977-984.
16. Rembold H. Biologically active substances in royal jelly. Vitam. Horm. 1965, 23:359-382.
17. Kohno K., Okamoto I., Sano O., Arai N., Iwaki K., Ikeda M., Kurimoto M. Royal jelly inhibits the production of proinflammatory cytokines by activated macrophages. Biosci. Biotechnol. Biochem. 2004, 68:138-145.
18. Tamura T., Fujii A., Kuboyama N. Antitumor effects of royal jelly(RJ). Folia Pharmacol. Japan 1987, 89:73-80.
19. Helleu C. Antibacterial properties of royal jelly; bactericidal and antibiotic effects of neutralized royal jelly. Ann. Inst. Pasteur. (Paris) 1956, 91:231-237.
20. Townsend G.F., Morgan J.F., Hazlett B. Activity of 10-hydroxydecenoic acid from royal jelly against experimental leukaemia and ascitic tumours. Nature 1959, 183:1270-1271.
21. Townsend G.F., Morgan J.F., Tolnai S., Hazlett B., Morton H.J., Shuel R.W. Studies on the in vitro antitumor activity of fatty acids. I. 10-Hydroxy-2-decenoic acid from royal jelly. Cancer Res. 1960, 20:503-510.
22. Blum M.S., Novak A.F., Taber S. 10-Hydroxy-delta 2-decenoic acid, an antibiotic found in royal jelly. Science 1959, 130:452-453.
23. Izuta H., Chikaraishi Y., Shimazawa M., Mishima S., Hara H. 10-Hydroxy-2-decenoic acid, a major fatty acid from royal jelly, inhibits VEGF-induced angiogenesis in human umbilical vein endothelial cells. eCAM 2009, 6:489-494.
24. Suzuki K.M., Isohama Y., Maruyama H., Yamada Y., Narita Y., Ohta S., Araki Y., Miyata T., Mishima S. Estrogenic activities of Fatty acids and a sterol isolated from royal jelly. eCAM 2008, 5:295-302.
25. Hattori N., Nomoto H., Fukumitsu H., Mishima S., Furukawa S. Royal jelly and its unique fatty acid, 10-hydroxy-trans-2-decenoic acid, promote neurogenesis by neural stem/progenitor cells in vitro. Biomed. Res. 2007, 28:261-266.
26. Kim Y.M., Lee B.S., Yi K.Y., Paik S.G. Upstream NF-kappaB site is required for the maximal expression of mouse inducible nitric oxide synthase gene in interferon-gamma plus lipopolysaccharide-induced RAW 264.7 macrophages. Biochem. Biophys. Res. Commun. 1997, 236:655-660.
27. Sugiyama T., Fujita M., Koide N., Mori I., Yoshida T., Mori H., Yokochi T. 2-aminopurine inhibits lipopolysaccharide-induced nitric oxide production by preventing IFN-beta production. Microbiol. Immunol. 2004, 48:957-963.
28. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 1982, 126:131-138.
29. Kamijo R., Harada H., Matsuyama T., Bosland M., Gerecitano J., Shapiro D., Le J., Koh S.I., Kimura T., Green S.J., et al. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 1994, 263:1612-1615.
30. Vila-del Sol V., Diaz-Munoz M.D., Fresno M. Requirement of tumor necrosis factor alpha and nuclear factor-kappaB in the induction by IFN-gamma of inducible nitric oxide synthase in macrophages. J. Leukoc. Biol. 2007, 81:272-283.
31. Shakhov A.N., Collart M.A., Vassalli P., Nedospasov S.A., Jongeneel C.V. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J. Exp. Med. 1990, 171:35-47.
32. Tsai E.Y., Jain J., Pesavento P.A., Rao A., Goldfeld A.E. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol. Cell. Biol. 1996, 16:459-467.
33. Falvo J.V., Brinkman B.M., Tsytsykova A.V., Tsai E.Y., Yao T.P., Kung A.L., Goldfeld A.E. A stimulus-specific role for CREB-binding protein (CBP) in T cell receptor-activated tumor necrosis factor alpha gene expression. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3925-3929.
34. Vila-del Sol V., Punzon C., Fresno M. IFN-gamma-induced TNF-alpha expression is regulated by interferon regulatory factors 1 and 8 in mouse macrophages. J. Immunol. 2008, 181:4461-4470.
35. Kantakamalakul W., Politis A.D., Marecki S., Sullivan T., Ozato K., Fenton M.J., Vogel S.N. Regulation of IFN consensus sequence binding protein expression in murine macrophages. J. Immunol. 1999, 162:7417-7425.
36. Scharton-Kersten T., Contursi C., Masumi A., Sher A., Ozato K. Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction. J. Exp. Med. 1997, 186:1523-1534.
37. Zhang J., Qian X., Ning H., Yang J., Xiong H., Liu J. Activation of IL-27 p28 gene transcription by interferon regulatory factor 8 in cooperation with interferon regulatory factor 1. J. Biol. Chem. 2010, 285:21269-21281.
38. Pflanz S., Timans J.C., Cheung J., Rosales R., Kanzler H., Gilbert J., Hibbert L., Churakova T., Travis M., Vaisberg E., Blumenschein W.M., Mattson J.D., Wagner J.L., To W., Zurawski S., McClanahan T.K., Gorman D.M., Bazan J.F., de Waal Malefyt R., Rennick D., Kastelein R.A. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002, 16:779-790.
39. Trinchieri G., Pflanz S., Kastelein R.A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003, 19:641-644.
40. McKenzie B.S., Kastelein R.A., Cua D.J. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006, 27:17-23.
41. Awasthi A., Murugaiyan G., Kuchroo V.K. Interplay between effector Th17 and regulatory T cells. J. Clin. Immunol. 2008, 28:660-670.
42. Schmidt C., Giese T., Ludwig B., Mueller-Molaian I., Marth T., Zeuzem S., Meuer S.C., Stallmach A. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm. Bowel Dis. 2005, 11:16-23.
43. Villarino A.V., Artis D., Bezbradica J.S., Miller O., Saris C.J., Joyce S., Hunter C.A. IL-27R deficiency delays the onset of colitis and protects from helminth-induced pathology in a model of chronic IBD. Int. Immunol. 2008, 20:739-752.
44. Leon A.J., Gomez E., Garrote J.A., Bernardo D., Barrera A., Marcos J.L., Fernandez-Salazar L., Velayos B., Blanco-Quiros A., Arranz E. High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD. Mediators Inflamm. 2009, 2009:580450.
45. Tucker P.C., Sack G.H. Expression of serum amyloid A genes in mouse brain: unprecedented response to inflammatory mediators. FASEB J. 2001, 15:2241-2246.
46. Caramalho I., Lopes-Carvalho T., Ostler D., Zelenay S., Haury M., Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med. 2003, 197:403-411.